Following outcomes of early inclisiran use after a heart attack
Observes heart attack patients who start inclisiran, a drug given to lower cholesterol.
Plain-language title generated from the registry record
Registry title: Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients
Key facts
- Where
- Cheboksary, Grozny, Kaluga, Kemerovo, Khanty-Mansiysk, Moscow, Novosibirsk, Orenburg, Penza, Petrozavodsk, Rostov-on-Don, S Petersburg, Samara, Syktyvkar, Tomsk, and Ulan-Ude, RussiaSee the 16 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07142265, who can take part
Where in Russia
- CheboksaryCheboksary, RussiaTaking people
- GroznyGrozny, RussiaTaking people
- KalugaKaluga, RussiaTaking people
- KemerovoKemerovo, RussiaTaking people
- Khanty-MansiyskKhanty-Mansiysk, RussiaTaking people
- MoscowMoscow, RussiaTaking people
- NovosibirskNovosibirsk, RussiaTaking people
- OrenburgOrenburg, RussiaTaking people
- PenzaPenza, RussiaTaking people
- PetrozavodskPetrozavodsk, RussiaTaking people
- Rostov-on-DonRostov-on-Don, RussiaTaking people
- S PetersburgS Petersburg, RussiaTaking people
- SamaraSamara, RussiaTaking people
- SyktyvkarSyktyvkar, RussiaTaking people
- TomskTomsk, RussiaTaking people
- Ulan-UdeUlan-Ude, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT07142265
- Record updated
- 10 August 2026
- Original description
Evaluation of clinical outcomes during 12 months after inclisiran initiation in patients after STEMI/non-STEMI in real-world settings in Russia. It is also planned to study the therapy effect on the lipid profile characteristics, its safety, the state of atherosclerotic plaques according to carotid ultrasound, the frequency of hospitalizations and the need for intensive follow-up.Read full original descriptionShow less
Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients
Evaluation of clinical outcomes during 12 months after inclisiran initiation in patients after STEMI/non-STEMI in real-world settings in Russia. It is also planned to study the therapy effect on the lipid profile characteristics, its safety, the state of atherosclerotic plaques according to carotid ultrasound, the frequency of hospitalizations and the need for intensive follow-up.
Inclusion: Adult patients of both genders; Myocardial Infarction diagnosis; Dyslipidemia diagnosis; The first injection of inclisiran no later than 14 ± 5 days after the STEMI/non-STEMI; LDL-C > 5 mmol/L (statin-naive patients) or LDL-C > 2.5 mmol/L (on the basis of statin MTD) at the time of hospitalization or no target LDL-C level (> 1.4 mmol/L or no LDL-C level decrease by 50% on statin MTD + ezetimibe); Signed Informed Consent Form (ICF).
Exclusion: Severe oncological and somatic diseases with system and organ failure*; Competing diseases that caused emergency hospitalization (pulmonary thromboembolism, aortic dissection); History of therapy with PCSK9 inhibitors; Active inflammatory liver disease or the levels of AST, ALT > 3 times, or total bilirubin > 2 times higher than the upper limit of norm; Any other MACE in the anamnesis.